131 related articles for article (PubMed ID: 16685529)
41. Pilot randomized phase II study of celecoxib in oral premalignant lesions.
Papadimitrakopoulou VA; William WN; Dannenberg AJ; Lippman SM; Lee JJ; Ondrey FG; Peterson DE; Feng L; Atwell A; El-Naggar AK; Nathan CO; Helman JI; Du B; Yueh B; Boyle JO
Clin Cancer Res; 2008 Apr; 14(7):2095-101. PubMed ID: 18381950
[TBL] [Abstract][Full Text] [Related]
42. Targeting cyclooxygenase-2 reduces overt toxicity toward low-dose vinblastine and extends survival of juvenile mice with Friend disease.
Cervi D; Klement G; Stempak D; Baruchel S; Koki A; Ben-David Y
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):712-9. PubMed ID: 15701860
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and tolerability of celecoxib in the treatment of acute gouty arthritis: a randomized controlled trial.
Schumacher HR; Berger MF; Li-Yu J; Perez-Ruiz F; Burgos-Vargas R; Li C
J Rheumatol; 2012 Sep; 39(9):1859-66. PubMed ID: 22859357
[TBL] [Abstract][Full Text] [Related]
44. Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy.
Pitot HC; Goldberg RM; Reid JM; Sloan JA; Skaff PA; Erlichman C; Rubin J; Burch PA; Adjei AA; Alberts SA; Schaaf LJ; Elfring G; Miller LL
Clin Cancer Res; 2000 Jun; 6(6):2236-44. PubMed ID: 10873073
[TBL] [Abstract][Full Text] [Related]
45. Irinotecan-based chemotherapy in a metastatic colorectal cancer patient under haemodialysis for chronic renal dysfunction: two cases considered.
Vénat-Bouvet L; Saint-Marcoux F; Lagarde C; Peyronnet P; Lebrun-Ly V; Tubiana-Mathieu N
Anticancer Drugs; 2007 Sep; 18(8):977-80. PubMed ID: 17667606
[TBL] [Abstract][Full Text] [Related]
46. Dose-finding phase I clinical and pharmacokinetic study of orally administered irinotecan in patients with advanced solid tumors.
Kuppens IE; Dansin E; Boot H; Feger C; Assadourian S; Bonneterre ME; Beijnen JH; Schellens JH; Bonneterre J
Clin Cancer Res; 2006 Jun; 12(12):3774-81. PubMed ID: 16778105
[TBL] [Abstract][Full Text] [Related]
47. Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11.
Trifan OC; Durham WF; Salazar VS; Horton J; Levine BD; Zweifel BS; Davis TW; Masferrer JL
Cancer Res; 2002 Oct; 62(20):5778-84. PubMed ID: 12384538
[TBL] [Abstract][Full Text] [Related]
48. Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecan.
Ma MK; Zamboni WC; Radomski KM; Furman WL; Santana VM; Houghton PJ; Hanna SK; Smith AK; Stewart CF
Clin Cancer Res; 2000 Mar; 6(3):813-9. PubMed ID: 10741701
[TBL] [Abstract][Full Text] [Related]
49. Irinotecan and UFT/leucovorin in patients with advanced cancers.
Stevenson JP; Redlinger M; Sun W; Haller D; O'Dwyer PJ
Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):91-2. PubMed ID: 11098504
[TBL] [Abstract][Full Text] [Related]
50. Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation.
Fabi A; Metro G; Papaldo P; Mottolese M; Melucci E; Carlini P; Sperduti I; Russillo M; Gelibter A; Ferretti G; Tomao S; Milella M; Cognetti F
Cancer Chemother Pharmacol; 2008 Sep; 62(4):717-25. PubMed ID: 18071704
[TBL] [Abstract][Full Text] [Related]
51. Antitumor enhancement of celecoxib, a selective Cyclooxygenase-2 inhibitor, in a Lewis lung carcinoma expressing Cyclooxygenase-2.
Park W; Oh YT; Han JH; Pyo H
J Exp Clin Cancer Res; 2008 Nov; 27(1):66. PubMed ID: 19000324
[TBL] [Abstract][Full Text] [Related]
52. Flat-fixed dosing of irinotecan: influence on pharmacokinetic and pharmacodynamic variability.
de Jong FA; Mathijssen RH; Xie R; Verweij J; Sparreboom A
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4068-71. PubMed ID: 15217940
[TBL] [Abstract][Full Text] [Related]
53. A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme.
Fadul CE; Kingman LS; Meyer LP; Cole BF; Eskey CJ; Rhodes CH; Roberts DW; Newton HB; Pipas JM
J Neurooncol; 2008 Nov; 90(2):229-35. PubMed ID: 18661102
[TBL] [Abstract][Full Text] [Related]
54. Cyclooxygenase-2 inhibitor, celecoxib, inhibits leiomyoma cell proliferation through the nuclear factor κB pathway.
Park SB; Jee BC; Kim SH; Cho YJ; Han M
Reprod Sci; 2014 Sep; 21(9):1187-95. PubMed ID: 25001017
[TBL] [Abstract][Full Text] [Related]
55. Elevated macrophage migration inhibitory factor and decreased transforming growth factor-beta levels in major depression--no influence of celecoxib treatment.
Musil R; Schwarz MJ; Riedel M; Dehning S; Cerovecki A; Spellmann I; Arolt V; Müller N
J Affect Disord; 2011 Nov; 134(1-3):217-25. PubMed ID: 21684012
[TBL] [Abstract][Full Text] [Related]
56. Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial.
Hayslip J; Chaudhary U; Green M; Meyer M; Dunder S; Sherman C; Salzer S; Kraft A; Montero AJ
BMC Cancer; 2007 Dec; 7():221. PubMed ID: 18053191
[TBL] [Abstract][Full Text] [Related]
57. Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma.
Grossman SA; Olson J; Batchelor T; Peereboom D; Lesser G; Desideri S; Ye X; Hammour T; Supko JG;
Neuro Oncol; 2008 Apr; 10(2):190-8. PubMed ID: 18287342
[TBL] [Abstract][Full Text] [Related]
58. Phase II evaluation of thalidomide in patients with metastatic breast cancer.
Baidas SM; Winer EP; Fleming GF; Harris L; Pluda JM; Crawford JG; Yamauchi H; Isaacs C; Hanfelt J; Tefft M; Flockhart D; Johnson MD; Hawkins MJ; Lippman ME; Hayes DF
J Clin Oncol; 2000 Jul; 18(14):2710-7. PubMed ID: 10894870
[TBL] [Abstract][Full Text] [Related]
59. Is celecoxib an inducer of cytochrome P450 3A4 in subjects carrying the CYP2C9*3 allele?
Rodrigues AD; Yang Z; Chen C; Pray D; Kim S; Sinz M
Clin Pharmacol Ther; 2006 Sep; 80(3):298-301; author reply 301-02. PubMed ID: 16952496
[No Abstract] [Full Text] [Related]
60. Celecoxib pathways: pharmacokinetics and pharmacodynamics.
Gong L; Thorn CF; Bertagnolli MM; Grosser T; Altman RB; Klein TE
Pharmacogenet Genomics; 2012 Apr; 22(4):310-8. PubMed ID: 22336956
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
